MTOR and gastric cancer: Patients with p-mTOR positive gastric cancer showed significantly shorter disease-free and overall survival rates than those with p-mTOR negative gastric cancer (DFS, 48.9% versus 30.1%; p = .006; OS, 51.1% versus 34.4%; p = .011; Table 2; Figure 2A, B).